_id
691846b93c536f8df23177ec
Ticker
ZBIO
Name
Zenas BioPharma, Inc. Common Stock
Exchange
NASDAQ
Address
852 Winter Street, Waltham, MA, United States, 02451
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://zenasbio.com
Description
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Last Close
15.05
Volume
2030991
Current Price
16.51
Change
1.31
Last Updated
2026-01-08T13:18:29.519Z
Image
https://logo.clearbit.com/zenasbio.com
Ipo Date
2024-09-13T00:00:00.000Z
Market Cap
1914199168
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.6785307692307693
Sentiment Sources
13
Rating
4.7143
Target Price
43.5714
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
5000000
Gross Profit
-5000000
Operating Expenses
47580000
Operating Income
-52580000
Interest Expense
-
Pretax Income
-51499000
Net Income
-51499000
Eps
-1.221532405393443
Dividends Per Share
-
Shares Outstanding
53679166
Income Tax Expense
-
EBITDA
-51488000
Operating Margin
-
Total Other Income Expense Net
1081000
Cash
115565000
Short Term Investments
175319000
Receivables
-
Inventories
-
Total Current Assets
296642000
Property Plant Equipment
857000
Total Assets
322018000
Payables
6444000
Short Term Debt
618000
Long Term Debt
-
Total Liabilities
125590000
Equity
196428000
Bs_currency_symbol
USD
Depreciation
11000
Change In Working Capital
-3664000
Cash From Operations
-41125000
Capital Expenditures
5000000
Cash From Investing
40043000
Cash From Financing
72616000
Net Change In Cash
71559000
Cf_currency_symbol
USD
PE
2.6086
PB
3.543541162156109
ROE
-26.21774899708799
ROA
-15.992584265475843
FCF
-46125000
Fcf Percent
-
Piotroski FScore
1
Health Score
34
Deep Value Investing Score
5
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
1.5
Growth Investing Score
0.5
Momentum Investing Score
3
Net Net Investing Score
2.5
Quality Investing Score
2
Value Investing Score
5.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
5000000
Quarters > 0 > income Statement > gross Profit
-5000000
Quarters > 0 > income Statement > operating Expenses
47580000
Quarters > 0 > income Statement > operating Income
-52580000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-51499000
Quarters > 0 > income Statement > net Income
-51499000
Quarters > 0 > income Statement > eps
-1.221532405393443
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
42159340
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-51488000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
1081000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
115565000
Quarters > 0 > balance Sheet > short Term Investments
175319000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
296642000
Quarters > 0 > balance Sheet > property Plant Equipment
857000
Quarters > 0 > balance Sheet > total Assets
322018000
Quarters > 0 > balance Sheet > payables
6444000
Quarters > 0 > balance Sheet > short Term Debt
618000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
125590000
Quarters > 0 > balance Sheet > equity
196428000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-51499000
Quarters > 0 > cash Flow > depreciation
11000
Quarters > 0 > cash Flow > change In Working Capital
-3664000
Quarters > 0 > cash Flow > cash From Operations
-41125000
Quarters > 0 > cash Flow > capital Expenditures
5000000
Quarters > 0 > cash Flow > cash From Investing
40043000
Quarters > 0 > cash Flow > cash From Financing
72616000
Quarters > 0 > cash Flow > net Change In Cash
71559000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-1.221532405393443
Quarters > 0 > ratios > PB
3.543541162156109
Quarters > 0 > ratios > ROE
-26.21774899708799
Quarters > 0 > ratios > ROA
-15.992584265475843
Quarters > 0 > ratios > FCF
-46125000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
34
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
43027000
Quarters > 1 > income Statement > gross Profit
-43027000
Quarters > 1 > income Statement > operating Expenses
12136000
Quarters > 1 > income Statement > operating Income
-55163000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-52203000
Quarters > 1 > income Statement > net Income
-52223000
Quarters > 1 > income Statement > eps
-1.2474023895627415
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
41865400
Quarters > 1 > income Statement > income Tax Expense
20000
Quarters > 1 > income Statement > EBITDA
-55151000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
2960000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
44006000
Quarters > 1 > balance Sheet > short Term Investments
229273000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
278603000
Quarters > 1 > balance Sheet > property Plant Equipment
1071000
Quarters > 1 > balance Sheet > total Assets
293085000
Quarters > 1 > balance Sheet > payables
7931000
Quarters > 1 > balance Sheet > short Term Debt
793000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
53459000
Quarters > 1 > balance Sheet > equity
239626000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-52223000
Quarters > 1 > cash Flow > depreciation
-923000
Quarters > 1 > cash Flow > change In Working Capital
5158000
Quarters > 1 > cash Flow > cash From Operations
-41743000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-112291000
Quarters > 1 > cash Flow > cash From Financing
1722000
Quarters > 1 > cash Flow > net Change In Cash
-152548000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-1.2474023895627415
Quarters > 1 > ratios > PB
2.884485631776185
Quarters > 1 > ratios > ROE
-21.793544940866184
Quarters > 1 > ratios > ROA
-17.81838033335039
Quarters > 1 > ratios > FCF
-41743000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
43
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
10000000
Quarters > 2 > income Statement > cost Of Revenue
23000
Quarters > 2 > income Statement > gross Profit
10000000
Quarters > 2 > income Statement > operating Expenses
47330000
Quarters > 2 > income Statement > operating Income
-37330000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-33778000
Quarters > 2 > income Statement > net Income
-33573000
Quarters > 2 > income Statement > eps
-0.8031664081469059
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
41800802
Quarters > 2 > income Statement > income Tax Expense
-205000
Quarters > 2 > income Statement > EBITDA
-33755000
Quarters > 2 > income Statement > operating Margin
-373.3
Quarters > 2 > income Statement > total Other Income Expense Net
3552000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
196554000
Quarters > 2 > balance Sheet > short Term Investments
115825000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
317807000
Quarters > 2 > balance Sheet > property Plant Equipment
1276000
Quarters > 2 > balance Sheet > total Assets
333766000
Quarters > 2 > balance Sheet > payables
20018000
Quarters > 2 > balance Sheet > short Term Debt
908000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
49449000
Quarters > 2 > balance Sheet > equity
284317000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-33573000
Quarters > 2 > cash Flow > depreciation
23000
Quarters > 2 > cash Flow > change In Working Capital
-8858000
Quarters > 2 > cash Flow > cash From Operations
-37051000
Quarters > 2 > cash Flow > capital Expenditures
18000
Quarters > 2 > cash Flow > cash From Investing
-86274000
Quarters > 2 > cash Flow > cash From Financing
99000
Quarters > 2 > cash Flow > net Change In Cash
-123278000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.8031664081469059
Quarters > 2 > ratios > PB
2.4273302019225023
Quarters > 2 > ratios > ROE
-11.808298483734704
Quarters > 2 > ratios > ROA
-10.058843620979967
Quarters > 2 > ratios > FCF
-37069000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-3.7069
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
5000000
Quarters > 3 > income Statement > cost Of Revenue
33000
Quarters > 3 > income Statement > gross Profit
5000000
Quarters > 3 > income Statement > operating Expenses
60623000
Quarters > 3 > income Statement > operating Income
-55623000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-52175000
Quarters > 3 > income Statement > net Income
-52604000
Quarters > 3 > income Statement > eps
-1.2587700406795883
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
41790000
Quarters > 3 > income Statement > income Tax Expense
429000
Quarters > 3 > income Statement > EBITDA
-55590000
Quarters > 3 > income Statement > operating Margin
-1112.4599999999998
Quarters > 3 > income Statement > total Other Income Expense Net
3448000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
319742000
Quarters > 3 > balance Sheet > short Term Investments
31024000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
355923000
Quarters > 3 > balance Sheet > property Plant Equipment
1189000
Quarters > 3 > balance Sheet > total Assets
369968000
Quarters > 3 > balance Sheet > payables
17136000
Quarters > 3 > balance Sheet > short Term Debt
785000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
57510000
Quarters > 3 > balance Sheet > equity
312458000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-52604000
Quarters > 3 > cash Flow > depreciation
33000
Quarters > 3 > cash Flow > change In Working Capital
8866000
Quarters > 3 > cash Flow > cash From Operations
-38554000
Quarters > 3 > cash Flow > capital Expenditures
74000
Quarters > 3 > cash Flow > cash From Investing
-3735000
Quarters > 3 > cash Flow > cash From Financing
1853000
Quarters > 3 > cash Flow > net Change In Cash
-40295000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.2587700406795883
Quarters > 3 > ratios > PB
2.2081460548297693
Quarters > 3 > ratios > ROE
-16.835542696938468
Quarters > 3 > ratios > ROA
-14.21852700774121
Quarters > 3 > ratios > FCF
-38628000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-7.7256
Quarters > 3 > health Score
35
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
5000000
Annuals > 0 > income Statement > cost Of Revenue
139139000
Annuals > 0 > income Statement > gross Profit
-134139000
Annuals > 0 > income Statement > operating Expenses
29749000
Annuals > 0 > income Statement > operating Income
-163888000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-156559000
Annuals > 0 > income Statement > net Income
-156988000
Annuals > 0 > income Statement > eps
-3.7569998316879007
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
41785469
Annuals > 0 > income Statement > income Tax Expense
429000
Annuals > 0 > income Statement > EBITDA
-163751000
Annuals > 0 > income Statement > operating Margin
-3277.7599999999998
Annuals > 0 > income Statement > total Other Income Expense Net
7329000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
319742000
Annuals > 0 > balance Sheet > short Term Investments
31024000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
355923000
Annuals > 0 > balance Sheet > property Plant Equipment
1189000
Annuals > 0 > balance Sheet > total Assets
369968000
Annuals > 0 > balance Sheet > payables
17136000
Annuals > 0 > balance Sheet > short Term Debt
785000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
57510000
Annuals > 0 > balance Sheet > equity
312458000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-156988000
Annuals > 0 > cash Flow > depreciation
137000
Annuals > 0 > cash Flow > change In Working Capital
25431000
Annuals > 0 > cash Flow > cash From Operations
-119674000
Annuals > 0 > cash Flow > capital Expenditures
131000
Annuals > 0 > cash Flow > cash From Investing
-30552000
Annuals > 0 > cash Flow > cash From Financing
412958000
Annuals > 0 > cash Flow > net Change In Cash
262889000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-3.7569998316879007
Annuals > 0 > ratios > PB
2.207906640860532
Annuals > 0 > ratios > ROE
-50.24291264745982
Annuals > 0 > ratios > ROA
-42.432859058080695
Annuals > 0 > ratios > FCF
-119805000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-23.961
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
50000000
Annuals > 1 > income Statement > cost Of Revenue
113000
Annuals > 1 > income Statement > gross Profit
50000000
Annuals > 1 > income Statement > operating Expenses
87147000
Annuals > 1 > income Statement > operating Income
-37147000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-36823000
Annuals > 1 > income Statement > net Income
-37124000
Annuals > 1 > income Statement > eps
-0.9688627948152739
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
38317087
Annuals > 1 > income Statement > income Tax Expense
301000
Annuals > 1 > income Statement > EBITDA
-27034000
Annuals > 1 > income Statement > operating Margin
-74.29400000000001
Annuals > 1 > income Statement > total Other Income Expense Net
324000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
56857000
Annuals > 1 > balance Sheet > short Term Investments
0
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
59804000
Annuals > 1 > balance Sheet > property Plant Equipment
1014000
Annuals > 1 > balance Sheet > total Assets
68180000
Annuals > 1 > balance Sheet > payables
5396000
Annuals > 1 > balance Sheet > short Term Debt
556000
Annuals > 1 > balance Sheet > long Term Debt
20300000
Annuals > 1 > balance Sheet > total Liabilities
293901000
Annuals > 1 > balance Sheet > equity
-225721000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-37124000
Annuals > 1 > cash Flow > depreciation
113000
Annuals > 1 > cash Flow > change In Working Capital
-8039000
Annuals > 1 > cash Flow > cash From Operations
-30529000
Annuals > 1 > cash Flow > capital Expenditures
17000
Annuals > 1 > cash Flow > cash From Investing
-17000
Annuals > 1 > cash Flow > cash From Financing
20116000
Annuals > 1 > cash Flow > net Change In Cash
-10352000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.9688627948152739
Annuals > 1 > ratios > PB
-2.802641785079811
Annuals > 1 > ratios > ROE
16.446852530336123
Annuals > 1 > ratios > ROA
-54.449985332942205
Annuals > 1 > ratios > FCF
-30546000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-0.61092
Annuals > 1 > health Score
27
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
61689000
Annuals > 2 > income Statement > gross Profit
-61689000
Annuals > 2 > income Statement > operating Expenses
14510000
Annuals > 2 > income Statement > operating Income
-76199000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-119282000
Annuals > 2 > income Statement > net Income
-119282000
Annuals > 2 > income Statement > eps
-3.1130237014102873
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
38317087
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-75121000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-43083000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
67209000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
68444000
Annuals > 2 > balance Sheet > property Plant Equipment
1801000
Annuals > 2 > balance Sheet > total Assets
74579000
Annuals > 2 > balance Sheet > payables
5815000
Annuals > 2 > balance Sheet > short Term Debt
715000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
266865000
Annuals > 2 > balance Sheet > equity
-192286000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-119282000
Annuals > 2 > cash Flow > depreciation
78000
Annuals > 2 > cash Flow > change In Working Capital
7967000
Annuals > 2 > cash Flow > cash From Operations
-65652000
Annuals > 2 > cash Flow > capital Expenditures
2198000
Annuals > 2 > cash Flow > cash From Investing
-2198000
Annuals > 2 > cash Flow > cash From Financing
59391000
Annuals > 2 > cash Flow > net Change In Cash
-8500000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-3.1130237014102873
Annuals > 2 > ratios > PB
-3.28996966170184
Annuals > 2 > ratios > ROE
62.03363739429808
Annuals > 2 > ratios > ROA
-159.9404658147736
Annuals > 2 > ratios > FCF
-67850000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
31
Valuation > metrics > PE
2.6086
Valuation > metrics > PB
3.543541162156109
Valuation > final Score
64.56458837843891
Valuation > verdict
27.9% Undervalued
Profitability > metrics > ROE
-26.21774899708799
Profitability > metrics > ROA
-17.360656953499504
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.6393691327102042
Risk > metrics > Interest Coverage
-4780
Risk > final Score
-19072
Risk > verdict
High
Liquidity > metrics > Current Ratio
42.00538091192297
Liquidity > metrics > Quick Ratio
42.00538091192297
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
15
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-15
Prev Risks > 1
-6432
Prev Risks > 2
-5
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:51:36.122Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-17
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-1.19
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-12
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-1.22
Earnings History > 1 > eps Estimate
-0.85
Earnings History > 1 > eps Difference
-0.37
Earnings History > 1 > surprise Percent
-43.5294
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-12
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-1.25
Earnings History > 2 > eps Estimate
-1.06
Earnings History > 2 > eps Difference
-0.19
Earnings History > 2 > surprise Percent
-17.9245
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-15
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.8
Earnings History > 3 > eps Estimate
-1.03
Earnings History > 3 > eps Difference
0.23
Earnings History > 3 > surprise Percent
22.3301
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-02-26
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-1.26
Earnings History > 4 > eps Estimate
-1.0187
Earnings History > 4 > eps Difference
-0.2413
Earnings History > 4 > surprise Percent
-23.6871
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-12
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-5.02
Earnings History > 5 > eps Estimate
-9.3
Earnings History > 5 > eps Difference
4.28
Earnings History > 5 > surprise Percent
46.0215
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-22
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
-2.79
Earnings History > 6 > eps Estimate
-1.24
Earnings History > 6 > eps Difference
-1.55
Earnings History > 6 > surprise Percent
-125
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO FinancialContent
Read more →Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contac - The National Law Review
1/19/2026
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contac The National Law Review
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$43.5714
Analyst Picks
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Medium
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Zenas BioPharma, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-1.19
Date
2025-09-30
EPS Actual
-1.22
EPS Estimate
-0.85
EPS Difference
-0.37
Surprise Percent
-43.5294%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.